In line with this, Shiraki et al. found that CD109+ glioma cells preferentially colocalized with CD44, a mesenchymal tumor subtype marker, to the PVN, suggesting a role of CD109+ cells in promoting GBM invasion [37,38]. The gene discussed is CD109; the disease is glioblastoma.